Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors | Scientific Reports
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
Survival Analysis in R
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Example Kaplan-Meier (KM) curves of overall survival (OS) from an... | Download Scientific Diagram
Median Survival Time - an overview | ScienceDirect Topics
Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
Kaplan-Meier survival analysis
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
a Kaplan–Meier survival curve with a median follow-up time of... | Download Scientific Diagram
Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Finding median survival time from survival function - Cross Validated
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Survival Analysis in R
The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
